IQVIA Laboratories published a new publication featuring the establishment of 353 molecularly characterized pediatric cancer PDX models by the ITCC-P4 platform.

As a leading global drug discovery and development laboratory services organization, IQVIA Laboratories provides a broad range of central laboratory and specialty biomarker services, including genomics, immunoassays, flow cytometry, anatomic pathology, precision medicine assays, vaccine assays, ADME, and bioanalytical services. IQVIA Laboratories also brings extensive expertise in antibody drug discovery, biomarker discovery, and decentralized clinical trial laboratory solutions. With a commitment to scientific excellence and operational efficiency, IQVIA Laboratories supports the entire drug discovery and development lifecycle across diverse regions and regulatory landscapes, ensuring data integrity and optimizing research to bring life-changing therapies to patients faster.